12
Participants
Start Date
March 4, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
June 30, 2026
Ketamine
Ketamine 0.50 mg/kg IM will be administered during the first dosing visit, and either 0.50 mg/kg IM or 0.75 mg/kg IM will be administered at the two subsequent dosing visits, depending on the participant's toleration of prior ketamine dose(s). All ketamine dosing visits will be facilitated by a licensed study therapist and clinician (i.e., NP or MD).
Psychotherapy
Psychotherapy will consist of three 1-hour preparatory talk therapy sessions over the 14 days preceding the first ketamine dosing visit, a 1-hour integration talk therapy session within 1-3 days following each ketamine dosing visit, and a final 1-hour integration talk therapy session about 1 week following the last ketamine visit. All talk therapy visits will be conducted by a licensed study therapist.
RECRUITING
San Francisco Department of Public Health, San Francicso
San Francisco Department of Public Health
OTHER_GOV
California HIV/AIDS Research Program
OTHER
National Center for Advancing Translational Sciences (NCATS)
NIH
Nicky Mehtani, MD, MPH
OTHER